RYTM — Rhythm Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$105.25
+$0.51 (+0.48%)
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ. It is led by David P. Meeker M.D., based in 222 Berkeley Street, Boston, MA, United States, 02116, with about 414 employees. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Latest reported RYTM revenue for 2025-09-30 was $51.3M. Net income was -$149.0M. Revenue was up 5.8% from 2025-06-30 to 2025-09-30. RYTM currently screens at market cap $6.49B.
Use this RYTM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RYTM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RYTM SEC filings page. Lician reads the product cache first so this HTML stays unique to Rhythm Pharmaceuticals Inc even when a live quote feed is slow.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Key Statistics
Market Cap
$6.49B
Volume
352,457
Previous Close
$111.44
Day Range
$111.79 – $114.07
P/B Ratio
50.08
EPS
-$4.34
Revenue
$130.13M
Net Income
-$260.60M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+68.1%
Profit Margin
-200.3%
Employees
414
RYTM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $130.13M | $77.43M | $23.64M | $3.15M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$260.60M | -$184.68M | -$181.12M | -$69.61M |
| EPS (Diluted) | -$4.34 | -$3.20 | -$3.47 | -$1.40 |
Total Assets
$392.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$89.14M
Operating Cash Flow
-$113.88M
Free Cash Flow
$0.00
Rhythm Pharmaceuticals Inc Company Information
- Chairman, President & CEO
- David P. Meeker M.D.
- Headquarters
- 222 Berkeley Street, Boston, MA, United States, 02116
- Website
- rhythmtx.com
- Phone
- 857 264 4280
- IPO / Founded
- 2017-10-05
- Sector
- Healthcare
- Industry
- Biotechnology